Lithuanian
Albanian
Arabic
Armenian
Azerbaijani
Belarusian
Bengali
Bosnian
Catalan
Czech
Danish
Deutsch
Dutch
English
Estonian
Finnish
Français
Greek
Haitian Creole
Hebrew
Hindi
Hungarian
Icelandic
Indonesian
Irish
Italian
Japanese
Korean
Latvian
Lithuanian
Macedonian
Mongolian
Norwegian
Persian
Polish
Portuguese
Romanian
Russian
Serbian
Slovak
Slovenian
Spanish
Swahili
Swedish
Turkish
Ukrainian
Vietnamese
Български
中文(简体)
中文(繁體)
non-alcoholic fatty liver disease/protease
Nuoroda įrašoma į mainų sritį
Puslapis 1 nuo 38 rezultatus
Isotretinoin in Treatment of COVID-19
Straipsnius versti gali tik registruoti vartotojai
Prisijungti Registracija
The study is a randomized interventional comparative Phase III trial. The duration of the trial for each subject is expected to be 3 months. The duration for each individual subject includes one-month study treatment and 3 months follow-up time. Recruitment of subjects will start in April 2020.
150
Optimal Clinical Predictors to AKI in Cirrhotic Patients Experienced Acute Gastrointestinal Hemorrhage
Straipsnius versti gali tik registruoti vartotojai
Prisijungti Registracija
Specific aims of this study :
1. To examine the influences of acute gastrointestinal hemorrhage on the serological or urinary level of novel renal biomarkers in patients with cirrhosis.
2. To investigate the ability of novel biomarkers to predict the development of acute kidney injury and the
Strategic Treatment Reduction in Very Early Liver Disease With 4 Weeks Sofosbuvir Plus Glecepravir-pibrentasvir
Straipsnius versti gali tik registruoti vartotojai
Prisijungti Registracija
The capacity to eliminate HCV through rapid direct acting antiviral (DAA) therapy scale-up would be enhanced by shortened duration therapy in key populations. The "next generation" DAA regimen of glecaprevir/pibrentasvir (300mg/120mg), an NS3/4a protease inhibitor and NS5A inhibitor, provides key
Clinical Trial to Evaluate the Efficacy of a Dyslipidemic Therapy in Mexican Population
Straipsnius versti gali tik registruoti vartotojai
Prisijungti Registracija
General objectives:
Evaluate the therapeutic efficacy in Mexican adults with dyslipidemia through the oral route use of L-carnitine + atorvastatin in comparison with the use of Atorvastatin, after six months of treatment.
Evaluate the safety of the medicines under study.
Hypothesis:
The combined use
Treatment of Chronic Delta Hepatitis With Lonafarnib, Ritonavir and Lambda Interferon
Straipsnius versti gali tik registruoti vartotojai
Prisijungti Registracija
Chronic delta hepatitis is a serious form of chronic liver disease caused by infection with the hepatitis D virus (HDV), a small RNA virus that requires farnesylation of its major structural protein (HDV antigen) for replication. Based on previous and ongoing clinical trials demonstrating
Effect on Liver Fat and Metabolic Parameters When Switching a Protease Inhibitor or Efavirenz to Raltegravir
Straipsnius versti gali tik registruoti vartotojai
Prisijungti Registracija
The prevalences of overweight (body-mass-index, BMI 25-30 kg/m2) and obesity (BMI>30 kg/m2) are steadily increasing among HIV-infected patients globally. In parallel, the risk of non-alcoholic fatty liver disease (NAFLD) increases. Clinically alarming are the data which suggest that HIV infected
Evaluating Treatment as Prevention Among People Who Inject Drugs in Dundee for HCV
Straipsnius versti gali tik registruoti vartotojai
Prisijungti Registracija
Hepatitis C is a blood-borne virus (HCV) that can seriously damage the liver and is spread mainly through blood-to-blood contact with an infected person. The "serious and significant public health risk" posed by HCV was recognised during a member's debate in the Scottish Parliament in 2004. By
HepCare: The Effectiveness of Community Based Interventions With Peer Support to Improve Case Detection, Carry Out Pre-treatment Assessments and Assist Underserved Populations Through HCV Treatment
Straipsnius versti gali tik registruoti vartotojai
Prisijungti Registracija
1. Introduction
Hepatitis C infection is a major cause of chronic liver disease and death throughout the world1. Approximately 3% of the world's population is infected with hepatitis C virus (HCV)2.
HCV is transmitted by blood and in the UK occurs primarily through injecting drug use. Chronically
Role of the Host Immunity in the Non-response to Direct Anti-viral Agent (DAA) Therapy
Straipsnius versti gali tik registruoti vartotojai
Prisijungti Registracija
Study objective and Hypothesis The underlying hypothesis of the project is that the level of anti-viral immune dysfunction in chronic HCV infection is a causal factor which can influence non-response to therapy. However, information about the features of individual anti-viral T cell responses
Real World Experience of Chronic Hepatitis C (CHC) Treatment in Israel
Straipsnius versti gali tik registruoti vartotojai
Prisijungti Registracija
The following data will be collected:
Demographics information: age, gender, race, country of birth (COB). Data on liver and virological characteristics: Hepatitis C virus(HCV) genotype, fibrosis stage (F0-4), technology of fibrosis assessment (fibroscan, fibrotest, elastography, biopsy), ,
Metformin Therapy in HCV Infection
Straipsnius versti gali tik registruoti vartotojai
Prisijungti Registracija
Safety, Tolerability and Efficacy of Sofosbuvir, Velpatasvir, and Voxilaprevir in Subjects With Previous DAA Experience
Straipsnius versti gali tik registruoti vartotojai
Prisijungti Registracija
The treatment of chronic Hepatitis C with combination directly acting antiviral agents (DAAs) represents a dramatic improvement over previous therapies in safety, tolerability and efficacy, but these therapies are not universally effective. Some patients fail to achieve sustained virologic response
Evaluation of the Effect of Gabexate Mesilate in the Hepatocyte Protection After Liver Resection
Straipsnius versti gali tik registruoti vartotojai
Prisijungti Registracija
Treatment of Chronic Delta Hepatitis With Lonafarnib and Ritonavir
Straipsnius versti gali tik registruoti vartotojai
Prisijungti Registracija
Chronic delta hepatitis is a serious form of chronic liver disease caused by infection with the hepatitis D virus (HDV), a small RNA virus that requires farnesylation of its major structural protein (HDV antigen) for replication. We propose to treat 21 adult patients with chronic delta hepatitis
Quantification of Side Effects During Hepatitis C Therapy
Straipsnius versti gali tik registruoti vartotojai
Prisijungti Registracija
Hepatitis C Virus infection is one of the main causes of chronic liver disease worldwide with current estimates of approximately 130 - 210 million individuals (according to 3% of the world population) chronically infected with the hepatitis C virus. However, hepatitis C virus infections are among
Išsamiausia vaistinių žolelių duomenų bazė, paremta mokslu
- Dirba 55 kalbomis
- Žolelių gydymas, paremtas mokslu
- Vaistažolių atpažinimas pagal vaizdą
- Interaktyvus GPS žemėlapis - pažymėkite vaistažoles vietoje (netrukus)
- Skaitykite mokslines publikacijas, susijusias su jūsų paieška
- Ieškokite vaistinių žolelių pagal jų poveikį
- Susitvarkykite savo interesus ir sekite naujienas, klinikinius tyrimus ir patentus
Įveskite simptomą ar ligą ir perskaitykite apie žoleles, kurios gali padėti, įveskite žolę ir pamatykite ligas bei simptomus, nuo kurių ji naudojama.
* Visa informacija pagrįsta paskelbtais moksliniais tyrimais
